|
1
|
Cairns P, Okami K, Halachmi S, Halachmi N,
Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS and Sidransky D:
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cancer Res. 57:4997–5000. 1997.PubMed/NCBI
|
|
2
|
Feilotter HE, Nagai MA, Boag AH, Eng C and
Mulligan LM: Analysis of PTEN and the 10q23 region in primary
prostate carcinomas. Oncogene. 16:1743–1748. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gray IC, Stewart LM, Phillips SM, Hamilton
JA, Gray NE, Watson GJ, Spurr NK and Snary D: Mutation and
expression analysis of the putative prostate tumour-suppressor gene
PTEN. Br J Cancer. 78:1296–1300. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li DM and Sun H: TEP1, encoded by a
candidate tumor suppressor locus, is a novel protein tyrosine
phosphatase regulated by transforming growth factor beta. Cancer
Res. 57:2124–2129. 1997.PubMed/NCBI
|
|
5
|
Steck PA, Pershouse MA, Jasser SA, Yung
WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T,
Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV: Identification
of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3
that is mutated in multiple advanced cancers. Nat Genet.
15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kolibaba KS and Druker BJ: Protein
tyrosine kinases and cancer. Biochim Biophys Acta. 1333:F217–F248.
1997.PubMed/NCBI
|
|
7
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stambolic V, Suzuki A, de la Pompa JL,
Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM,
Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent
cell survival by the tumor suppressor PTEN. Cell. 95:29–39. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun H, Lesche R, Li DM, Liliental J, Zhang
H, Gao J, Gavrilova N, Mueller B, Liu X and Wu H: PTEN modulates
cell cycle progression and cell survival by regulating
phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B
signaling pathway. Proc Natl Acad Sci USA. 96:6199–6204. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blanco-Aparicio C, Renner O, Leal JF and
Carnero A: PTEN, more than the AKT pathway. Carcinogenesis.
28:1379–1386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Georgescu MM, Kirsch KH, Kaloudis P, Yang
H, Pavletich NP and Hanafusa H: Stabilization and productive
positioning roles of the C2 domain of PTEN tumor suppressor. Cancer
Res. 60:7033–7038. 2000.PubMed/NCBI
|
|
13
|
Gildea JJ, Herlevsen M, Harding MA,
Gulding KM, Moskaluk CA, Frierson HF and Theodorescu D: PTEN can
inhibit in vitro organotypic and in vivo orthotopic invasion of
human bladder cancer cells even in the absence of its lipid
phosphatase activity. Oncogene. 23:6788–6797. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koul D, Jasser SA, Lu Y, Davies MA, Shen
R, Shi Y, Mills GB and Yung WK: Motif analysis of the tumor
suppressor gene MMAC/PTEN identifies tyrosines critical for tumor
suppression and lipid phosphatase activity. Oncogene. 21:2357–2364.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maier D, Jones G, Li X, Schonthal AH,
Gratzl O, Van Meir EG and Merlo A: The PTEN lipid phosphatase
domain is not required to inhibit invasion of glioma cells. Cancer
Res. 59:5479–5482. 1999.PubMed/NCBI
|
|
16
|
Bachoo RM, Maher EA, Ligon KL, Sharpless
NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R,
Rowitch DH, Louis DN and DePinho RA: Epidermal growth factor
receptor and Ink4a/Arf: convergent mechanisms governing terminal
differentiation and transformation along the neural stem cell to
astrocyte axis. Cancer Cell. 1:269–277. 2002. View Article : Google Scholar
|
|
17
|
Bajenaru ML, Hernandez MR, Perry A, Zhu Y,
Parada LF, Garbow JR and Gutmann DH: Optic nerve glioma in mice
requires astrocyte Nf1 gene inactivation and Nf1 brain
heterozygosity. Cancer Res. 63:8573–8577. 2003.PubMed/NCBI
|
|
18
|
Holland EC: Gliomagenesis: genetic
alterations and mouse models. Nat Rev Genet. 2:120–129. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uhrbom L, Dai C, Celestino JC, Rosenblum
MK, Fuller GN and Holland EC: Ink4a-Arf loss cooperates with KRas
activation in astrocytes and neural progenitors to generate
glioblastomas of various morphologies depending on activated Akt.
Cancer Res. 62:5551–5558. 2002.PubMed/NCBI
|
|
20
|
Bonni A, Sun Y, Nadal-Vicens M, Bhatt A,
Frank DA, Rozovsky I, Stahl N, Yancopoulos GD and Greenberg ME:
Regulation of gliogenesis in the central nervous system by the
JAK-STAT signaling pathway. Science. 278:477–483. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshimatsu T, Kawaguchi D, Oishi K, Takeda
K, Akira S, Masuyama N and Gotoh Y: Non-cell-autonomous action of
STAT3 in maintenance of neural precursor cells in the mouse
neocortex. Development. 133:2553–2563. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rahaman SO, Harbor PC, Chernova O, Barnett
GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active
Stat3 suppresses proliferation and induces apoptosis in
glioblastoma multiforme cells. Oncogene. 21:8404–8413. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weissenberger J, Loeffler S, Kappeler A,
Kopf M, Lukes A, Afanasieva TA, Aguzzi A and Weis J: IL-6 is
required for glioma development in a mouse model. Oncogene.
23:3308–3316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de la Iglesia N, Konopka G, Puram SV, Chan
JA, Bachoo RM, You MJ, Levy DE, Depinho RA and Bonni A:
Identification of a PTEN-regulated STAT3 brain tumor suppressor
pathway. Genes Dev. 22:449–462. 2008.PubMed/NCBI
|
|
25
|
Papagiannakopoulos T and Kosik KS:
MicroRNAs: regulators of oncogenesis and stemness. BMC Med.
6:152008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dick JE: Normal and leukemic human stem
cells assayed in SCID mice. Semin Immunol. 8:197–206. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F and
Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic
stem cells. Nat Med. 12:1167–1174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Al-Hajj M and Clarke MF: Self-renewal and
solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rich JN: Cancer stem cells in radiation
resistance. Cancer Res. 67:8980–8984. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Inoue A, Takahashi H, Harada H, Kohno S,
Ohue S, Kobayashi K, Yano H, Tanaka J and Ohnishi T: Cancer
stem-like cells of glioblastoma characteristically express MMP-13
and display highly invasive activity. Int J Oncol. 37:1121–1131.
2010.PubMed/NCBI
|
|
31
|
Wang H, Zhang W, Huang HJ, Liao WS and
Fuller GN: Analysis of the activation status of Akt, NFkappaB, and
Stat3 in human diffuse gliomas. Lab Invest. 84:941–951. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
33
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Nagayasu T and Sekine I: Expression of p-STAT3 in
human colorectal adenocarcinoma and adenoma; correlation with
clinicopathological factors. J Clin Pathol. 58:833–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Korkaya H, Liu S and Wicha MS: Regulation
of cancer stem cells by cytokine networks: attacking cancer’s
inflammatory roots. Clin Cancer Res. 17:6125–6129. 2011.PubMed/NCBI
|
|
35
|
Marotta LL, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ,
Choudhury SA, Maruyama R, Wu Z, Gonen M, Mulvey LA, Bessarabova MO,
Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson
AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA
and Polyak K: The JAK2/STAT3 signaling pathway is required for
growth of CD44CD24 stem cell-like breast cancer cells in human
tumors. J Clin Invest. 121:2723–2735. 2011. View Article : Google Scholar : PubMed/NCBI
|
